These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33544464)

  • 1. Direct comparison of the immunogenicity of major histocompatibility complex-I and -II deficient mesenchymal stem cells
    Halm D; Leibig N; Martens J; Stark GB; Groß T; Zimmermann S; Finkenzeller G; Lampert F
    Biol Chem; 2021 May; 402(6):693-702. PubMed ID: 33544464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.
    Berglund AK; Schnabel LV
    Equine Vet J; 2017 Jul; 49(4):539-544. PubMed ID: 27862236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells.
    Zangi L; Margalit R; Reich-Zeliger S; Bachar-Lustig E; Beilhack A; Negrin R; Reisner Y
    Stem Cells; 2009 Nov; 27(11):2865-74. PubMed ID: 19750539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.
    Schnabel LV; Pezzanite LM; Antczak DF; Felippe MJ; Fortier LA
    Stem Cell Res Ther; 2014 Jan; 5(1):13. PubMed ID: 24461709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells.
    Berglund AK; Fortier LA; Antczak DF; Schnabel LV
    Stem Cell Res Ther; 2017 Dec; 8(1):288. PubMed ID: 29273086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Immunological Mechanisms of Mesenchymal Stem Cells in Allogeneic Transplantation: From the Aspect of Major Histocompatibility Complex Class I.
    Wang Y; Tian M; Wang F; Heng BC; Zhou J; Cai Z; Liu H
    Stem Cells Dev; 2019 Sep; 28(17):1141-1150. PubMed ID: 31215341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart.
    Huang XP; Ludke A; Dhingra S; Guo J; Sun Z; Zhang L; Weisel RD; Li RK
    FASEB J; 2016 Sep; 30(9):3069-82. PubMed ID: 27221978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-induced increase in Sug1 leads to poor post-transplantation survival of allogeneic mesenchymal stem cells.
    Abu-El-Rub E; Sareen N; Lester Sequiera G; Ammar HI; Yan W; ShamsEldeen AM; Rubinchik I; Moudgil M; Shokry HS; Rashed LA; Dhingra S
    FASEB J; 2020 Sep; 34(9):12860-12876. PubMed ID: 32770803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to allogeneic equine mesenchymal stromal cells.
    Kamm JL; Riley CB; Parlane NA; Gee EK; McIlwraith CW
    Stem Cell Res Ther; 2021 Nov; 12(1):570. PubMed ID: 34772445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers.
    Berglund AK; Fisher MB; Cameron KA; Poole EJ; Schnabel LV
    Front Vet Sci; 2017; 4():84. PubMed ID: 28660198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants.
    de la Garza-Rodea AS; Verweij MC; Boersma H; van der Velde-van Dijke I; de Vries AA; Hoeben RC; van Bekkum DW; Wiertz EJ; Knaän-Shanzer S
    PLoS One; 2011 Jan; 6(1):e14493. PubMed ID: 21253016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-induced 26S proteasome dysfunction increases immunogenicity of mesenchymal stem cells.
    Abu-El-Rub E; Sequiera GL; Sareen N; Yan W; Moudgil M; Sabbir MG; Dhingra S
    Cell Death Dis; 2019 Jan; 10(2):90. PubMed ID: 30692516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histocompatibility testing of cultivated human bone marrow stromal cells - a promising step towards pre-clinical screening for allogeneic stem cell therapy.
    Koppula PR; Chelluri LK; Polisetti N; Vemuganti GK
    Cell Immunol; 2009; 259(1):61-5. PubMed ID: 19577229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC Class I Enables MSCs to Evade NK-Cell-Mediated Cytotoxicity and Exert Immunosuppressive Activity.
    Oh JY; Kim H; Lee HJ; Lee K; Barreda H; Kim HJ; Shin E; Bae EH; Kaur G; Zhang Y; Kim E; Lee JY; Lee RH
    Stem Cells; 2022 Sep; 40(9):870-882. PubMed ID: 35852488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo.
    Isakova IA; Lanclos C; Bruhn J; Kuroda MJ; Baker KC; Krishnappa V; Phinney DG
    PLoS One; 2014; 9(1):e87238. PubMed ID: 24489878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The systemic cellular immune response against allogeneic mesenchymal stem cells is influenced by inflammation, differentiation and MHC compatibility:
    Cequier A; Vázquez FJ; Vitoria A; Bernad E; Fuente S; Serrano MB; Zaragoza MP; Romero A; Rodellar C; Barrachina L
    Front Vet Sci; 2024; 11():1391872. PubMed ID: 38957800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes.
    Ranera B; Antczak D; Miller D; Doroshenkova T; Ryan A; McIlwraith CW; Barry F
    Equine Vet J; 2016 Mar; 48(2):253-60. PubMed ID: 25582202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo.
    Poncelet AJ; Vercruysse J; Saliez A; Gianello P
    Transplantation; 2007 Mar; 83(6):783-90. PubMed ID: 17414713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stem cells home to inflamed ocular surface and suppress allosensitization in corneal transplantation.
    Omoto M; Katikireddy KR; Rezazadeh A; Dohlman TH; Chauhan SK
    Invest Ophthalmol Vis Sci; 2014 Sep; 55(10):6631-8. PubMed ID: 25228546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.
    Cequier A; Vázquez FJ; Romero A; Vitoria A; Bernad E; García-Martínez M; Gascón I; Barrachina L; Rodellar C
    Front Vet Sci; 2022; 9():957153. PubMed ID: 36337202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.